• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有置信区间的多药效应分析

Multiple drug effect analysis with confidence interval.

作者信息

Belen'kii M S, Schinazi R F

机构信息

Veterans Affairs Medical Center, Decatur, GA 30033.

出版信息

Antiviral Res. 1994 Sep;25(1):1-11. doi: 10.1016/0166-3542(94)90089-2.

DOI:10.1016/0166-3542(94)90089-2
PMID:7811057
Abstract

The development of mathematical models for determining antagonism, synergy or additivism for drug combinations is becoming increasingly important in medical research and medicine. This paper describes improvements in the Chou and Talalay method which provides for the first time confidence intervals for the combination index. The Monte Carlo technique was used to calculate the confidence intervals and to obtain the new parameters which are needed for the modified interaction diagnosis. This new method can be adapted to current as well as future formulae used to evaluate drug combinations. Programs written in Microsoft and Visual Basic were developed for use on commonly available personal computers which we call Combostat.

摘要

在医学研究和医学领域,开发用于确定药物组合的拮抗作用、协同作用或相加作用的数学模型变得越来越重要。本文描述了周和塔拉莱方法的改进,该方法首次提供了组合指数的置信区间。蒙特卡罗技术用于计算置信区间并获得修改后的相互作用诊断所需的新参数。这种新方法可适用于当前以及未来用于评估药物组合的公式。我们用微软和Visual Basic编写了程序,以便在常用的个人计算机上使用,我们将其称为Combostat。

相似文献

1
Multiple drug effect analysis with confidence interval.具有置信区间的多药效应分析
Antiviral Res. 1994 Sep;25(1):1-11. doi: 10.1016/0166-3542(94)90089-2.
2
Monte Carlo simulation of parameter confidence intervals for non-linear regression analysis of biological data using Microsoft Excel.利用 Microsoft Excel 对生物数据的非线性回归分析进行参数置信区间的蒙特卡罗模拟。
Comput Methods Programs Biomed. 2012 Aug;107(2):155-63. doi: 10.1016/j.cmpb.2011.05.009. Epub 2011 Jul 18.
3
Interaction index and different methods for determining drug interaction in combination therapy.联合治疗中相互作用指数及确定药物相互作用的不同方法。
J Biopharm Stat. 2007;17(3):461-80. doi: 10.1080/10543400701199593.
4
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.紫杉醇、拓扑替康和顺铂对人畸胎瘤细胞生长的协同作用和拮抗作用的计算机定量分析:临床方案设计的合理方法
J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24. doi: 10.1093/jnci/86.20.1517.
5
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.药物联合研究中协同作用和拮抗作用的理论基础、实验设计及计算机模拟
Pharmacol Rev. 2006 Sep;58(3):621-81. doi: 10.1124/pr.58.3.10.
6
Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.使用非线性混合效应模型量化协同作用/拮抗作用:一项模拟研究。
Stat Med. 2008 Mar 30;27(7):1040-61. doi: 10.1002/sim.3005.
7
Drug combination studies and their synergy quantification using the Chou-Talalay method.药物联合研究及其协同作用的定量分析——Chou-Talalay 法
Cancer Res. 2010 Jan 15;70(2):440-6. doi: 10.1158/0008-5472.CAN-09-1947. Epub 2010 Jan 12.
8
Preclinical versus clinical drug combination studies.临床前与临床药物联合研究。
Leuk Lymphoma. 2008 Nov;49(11):2059-80. doi: 10.1080/10428190802353591.
9
A brief introduction to Monte Carlo simulation.蒙特卡洛模拟简介。
Clin Pharmacokinet. 2001 Jan;40(1):15-22. doi: 10.2165/00003088-200140010-00002.
10
Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.抗病毒研究中百分比数据与对数数据的三维协同分析比较。
Antiviral Res. 2017 Sep;145:1-5. doi: 10.1016/j.antiviral.2017.06.022. Epub 2017 Jul 1.

引用本文的文献

1
Novel 1'-homo--2'-deoxy-α-nucleosides: synthesis, characterization and biological activity.新型1'-高-2'-脱氧-α-核苷:合成、表征及生物活性
RSC Adv. 2020;10(27):15815-15824. doi: 10.1039/D0RA03254A. Epub 2020 Apr 21.
2
Anti-HIV activity of new pyrazolobenzothiazine 5,5-dioxide-based acetohydrazides.新型基于5,5-二氧化吡唑并苯并噻嗪的乙酰肼的抗HIV活性
Med Chem Res. 2015 Oct;24(10):3671-3680. doi: 10.1007/s00044-015-1411-z. Epub 2015 Jul 19.
3
Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-Triazol)-()-2-Methyl-but-2-Enyl Nucleoside Phosphonate Prodrugs.
(1,4-二取代-1,2,3-三唑基)-()-2-甲基-2-丁烯基核苷膦酸酯前药的合成与抗病毒活性评价。
Molecules. 2021 Mar 9;26(5):1493. doi: 10.3390/molecules26051493.
4
The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.MDM2 抑制剂 CGM097 联合 BET 抑制剂 OTX015 可诱导神经母细胞瘤模型中的细胞死亡并抑制肿瘤生长。
Cancer Med. 2020 Nov;9(21):8144-8158. doi: 10.1002/cam4.3407. Epub 2020 Oct 9.
5
Design, Synthesis, and Biological Evaluation of Novel Biotinylated Podophyllotoxin Derivatives as Potential Antitumor Agents.新型生物素化鬼臼毒素衍生物作为潜在抗肿瘤药物的设计、合成及生物学评价
Front Chem. 2019 Jun 18;7:434. doi: 10.3389/fchem.2019.00434. eCollection 2019.
6
Ecotoxicity of disinfectant benzalkonium chloride and its mixture with antineoplastic drug 5-fluorouracil towards alga .消毒剂苯扎氯铵及其与抗肿瘤药物5-氟尿嘧啶的混合物对藻类的生态毒性
PeerJ. 2018 Jun 18;6:e4986. doi: 10.7717/peerj.4986. eCollection 2018.
7
Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages.原代人单核细胞衍生巨噬细胞感染HIV-1和HIV-2期间的代谢谱分析。
Virology. 2016 Apr;491:106-14. doi: 10.1016/j.virol.2016.01.023. Epub 2016 Feb 16.
8
Analysis of drug combinations: current methodological landscape.药物联合分析:当前方法学全景。
Pharmacol Res Perspect. 2015 Jun;3(3):e00149. doi: 10.1002/prp2.149. Epub 2015 May 20.
9
Molecular docking and antiviral activity of N-substituted benzyl/phenyl-2-(3,4-dimethyl-5,5-dioxidopyrazolo[4,3-c][1,2]benzothiazin-2(4H)-yl)acetamides.N-取代苄基/苯基-2-(3,4-二甲基-5,5-二氧代吡唑并[4,3-c][1,2]苯并噻嗪-2(4H)-基)乙酰胺的分子对接及抗病毒活性
Bioorg Med Chem Lett. 2015 Mar 15;25(6):1348-51. doi: 10.1016/j.bmcl.2015.01.007. Epub 2015 Jan 22.
10
Synthesis and anti-HIV-1 screening of novel N'-(1-(aryl)ethylidene)-2-(5,5-dioxido-3-phenylbenzo[e]pyrazolo[4,3-c][1,2]thiazin-4(1H)-yl)acetohydrazides.新型N'-(1-(芳基)亚乙基)-2-(5,5-二氧代-3-苯基苯并[e]吡唑并[4,3-c][1,2]噻嗪-4(1H)-基)乙酰肼的合成及抗HIV-1筛选
Arch Pharm Res. 2014 Nov;37(11):1380-93. doi: 10.1007/s12272-013-0200-9. Epub 2013 Jul 10.